Therapeutic areas
Ten disclosed therapeutic areas, twelve disclosed Phase 1 programmes and thirteen clinical-stage programmes in total. The portfolio covers high-consequence viral, prion and bacterial disease, with the containment practice matched to each pathogen and indication.
Cleared for public release · public content date 31 July 2026 · internal revision 41. One section was withheld from this page under the disclosure policy. Requests for material retained but not published: disclosure@baxtra.pages.dev.
Therapeutic area · Risk Group 4
Henipaviruses & Emerging Zoonoses
Nipah virus kills between four and seven of every ten people it infects, spills over from fruit bats almost every year, and has no approved treatment of any kind.
Nipah is a paramyxovirus carried by Pteropus fruit bats. It reaches people through raw date-palm sap, through intermediate livestock, and directly from other people — caregivers and clinicians are repeatedly infected in Bangladesh and India. It kills through encephalitis: the virus fuses infected cells into syncytia and destroys the endothelium of the small vessels of the brain. Survivors are not reliably safe either, since relapsing and late-onset encephalitis can appear months to years after apparent recovery.
BX-101 is an oral inhibitor of the henipavirus fusion (F) glycoprotein. It binds a hydrophobic pocket in the prefusion trimer and holds it there, so the refolding step that drives the viral envelope into the host membrane never happens. Entry is blocked and syncytia do not form. We selected the molecule for brain penetration — unbound brain-to-plasma ratio 0.42 — over more potent analogues that stay in the periphery, because a drug that cannot reach the brain cannot treat this disease. The conserved pocket also gives coverage of Hendra virus and both Nipah genotypes.
Programme: BX-101 (Nipavir) — Phase 1, SENTINEL-1 · handled at BSL-4
Conditions in scope
- Nipah virus infection, Bangladesh genotype
- Nipah virus infection, Malaysia genotype
- Hendra virus infection
- Post-exposure prophylaxis in contacts
At a glance
- Case fatality 40–75%, up to ~90% in some Bangladesh outbreaks
- Biosafety level 4, positive-pressure suit
- WHO priority pathogen
- No licensed vaccine or therapeutic
Therapeutic area · Risk Group 4
Filovirus Disease
Marburg virus disease has killed as many as 88% of the people infected in a single outbreak. There is no licensed vaccine and no licensed therapeutic.
Marburg and its relative Ravn virus sit alongside the ebolaviruses in the family Filoviridae. Introduction is usually from Egyptian rousette bats, and the outbreak that follows is amplified inside hospitals: transmission is by contact with blood and body fluids, and the people caring for the first patient are the ones who get it. Care is delivered in an isolation unit in full encapsulating personal protective equipment, and even after recovery the virus can persist for months in immune-privileged sites.
BX-204 is a nucleoside analogue. Its intracellular triphosphate is accepted by the filovirus L protein polymerase, which then terminates the chain a few nucleotides later and, at sustained exposure, mutates the genome past viability. We targeted the catalytic core rather than a surface protein deliberately, so that one agent covers Marburg, Ravn, Zaire and Sudan. When an outbreak is declared the species is often confirmed days after the first treatment decision has to be made. Intravenous loading is for the patient already in an isolation unit; the oral step-down is for the one who is not.
Programme: BX-204 (Marburavir) — Phase 1, CORDON-1 · handled at BSL-4
BX-806 (Sudanavir) is the separate Sudan ebolavirus programme. It is an intravenous two-antibody cocktail: one antibody binds the GP2 fusion loop and the other the GP1 glycan cap, blocking entry at two distinct points on the Sudan ebolavirus surface glycoprotein. The programme is designed for a disease in which care is often delivered late, after dehydration, shock and organ injury have already developed.
Programme: BX-806 (Sudanavir) — Phase 1, KEYSTONE-1 · handled at BSL-4
See it in the pipeline Sudanavir fact sheet Medicines reference
Conditions in scope
- Marburg virus disease
- Ravn virus disease
- Zaire ebolavirus disease (secondary)
- Sudan ebolavirus disease (secondary)
- Sudan ebolavirus disease — BX-806
At a glance
- Case fatality 24–88% across recorded outbreaks
- Biosafety level 4, positive-pressure suit
- Category A infectious substance for transport
- Documented post-recovery viral persistence
Therapeutic area · special containment practice
Prion & Protein-Misfolding Disease
Creutzfeldt–Jakob disease is universally fatal, usually within six months of the first symptom, and nothing on the market changes that.
A prion is not a virus. It is the body’s own prion protein, misfolded, templating that same misfold onto every normal copy it meets. There is no genome to attack and no immune response to boost. The agent is also extraordinarily durable: it survives standard autoclaving, alcohol, formaldehyde and ionising radiation, which is why contaminated neurosurgical instruments are destroyed outright or treated with 1N sodium hydroxide and a 134°C extended steam cycle, and why prion work runs under its own containment practice rather than the ordinary rules.
BX-308 does not chase the misfolded species. It lowers the supply of the substrate. A gapmer antisense oligonucleotide recruits RNase H1 to PRNP transcripts, reducing normal cellular prion protein — the raw material every prion strain needs, whether the disease is sporadic, inherited or acquired. That makes the approach strain-agnostic in principle. It is given intrathecally because the disease lives in a compartment a systemic drug does not reach, and cerebrospinal prion protein gives us a pharmacodynamic readout at every visit. At 40 mg we are seeing 38% lowering.
Programme: BX-308 (Prionex) — Phase 1, VIGIL-0 · containment level 3 with prion practice
Conditions in scope
- Sporadic Creutzfeldt–Jakob disease
- Genetic CJD and fatal familial insomnia
- Gerstmann–Sträussler–Scheinker syndrome
- Asymptomatic PRNP variant carriers (registry)
At a glance
- Case fatality ~100%; median survival 4–6 months
- Resists standard autoclave, alcohol and formalin
- Single-use instruments; NaOH plus 134°C extended cycle
- No treatment has ever been approved
Therapeutic area · Risk Group 4
Viral Haemorrhagic Fever
Crimean-Congo haemorrhagic fever is carried by ticks across some thirty countries, kills up to four in ten, and infects the clinicians who treat it.
CCHF is the most geographically widespread of the tick-borne viral haemorrhagic fevers, endemic across the Balkans, the Middle East, Central Asia and much of Africa, and expanding as the range of Hyalomma ticks expands. People are infected by tick bite, by slaughtering infected livestock, and by contact with the blood of another patient — nosocomial transmission is well documented and often the way an outbreak is first recognised. There is no approved therapeutic; the evidence for ribavirin has never been conclusive.
BX-412 is two non-competing human IgG1 antibodies given together. One binds a conserved epitope on the Gc fusion loop and blocks pH-dependent fusion in the endosome; the other binds the GP38 accessory glycoprotein and recruits Fc-mediated clearance. They were paired specifically so that a virus escaping one is still neutralised by the other. The observed 26-day half-life supports a single infusion, and a single infusion is the only realistic regimen in the rural district hospitals where CCHF actually presents.
Programme: BX-412 (Cehafex) — Phase 1, BASTION-1 · handled at BSL-4
Conditions in scope
- Crimean-Congo haemorrhagic fever
- Post-exposure prophylaxis for exposed healthcare workers
- Lassa fever — BX-515, Phase 1
- Andes hantavirus syndrome — BX-733, Phase 1
At a glance
- Case fatality 10–40%
- Biosafety level 4; WHO priority pathogen
- Endemic in approximately 30 countries
- Documented healthcare-worker transmission
Therapeutic area · Risk Group 3
Lyssavirus & Neurotropic Infection
Rabies is preventable before symptoms begin, but once clinical signs appear the infection is almost invariably fatal. Approximately 59,000 people die of rabies each year, overwhelmingly in Asia and Africa and disproportionately as children.
Rabies virus is maintained chiefly in mammals, with domestic dogs responsible for most human deaths. Virus in saliva enters through a bite or other exposure, travels along peripheral nerves and reaches the central nervous system. The clinical illness may present as furious rabies with agitation and hydrophobia or as paralytic rabies, followed by encephalomyelitis, coma and death. Other lyssaviruses, including bat-associated viruses, can cause a similar neurological syndrome.
Wound washing, vaccine and rabies immunoglobulin prevent disease when given promptly after an exposure and before symptoms develop. They do not provide a dependable rescue once the virus has reached the central nervous system. Intensive care and experimental protocols have not produced a licensed treatment for symptomatic rabies, which is the gap BX-620 is intended to address.
BX-620 (Rabivex) is designed to penetrate the central nervous system and inhibit the lyssavirus L-protein polymerase, the enzyme that copies viral RNA. It is being studied as an intravenous treatment with an intrathecal loading dose to put exposure at the site of established infection; the route and dose are protocol-directed and do not make the candidate suitable for use outside the clinical study.
Programme: BX-620 (Rabivex) — Phase 1, LANTERN-1
Conditions in scope
- Symptomatic rabies encephalomyelitis
- Failed or delayed post-exposure prophylaxis
- Rabies virus infection
- Phylogroup I non-rabies lyssavirus infection
At a glance
- Approximately 59,000 deaths each year
- Nearly 100% fatal after clinical onset
- Dog-mediated transmission causes most deaths
- No approved treatment for symptomatic disease
Therapeutic area · Risk Group 3
Hantavirus & Vascular Leak Syndromes
Hantavirus cardiopulmonary syndrome can move from a non-specific febrile illness to pulmonary oedema and shock within hours. Andes orthohantavirus has a reported case fatality of approximately 35–40 per cent.
New World hantaviruses are carried by rodents and are acquired mainly by inhaling aerosolised material contaminated by rodent urine, faeces or saliva. Andes virus is associated particularly with long-tailed rice rats in Argentina and Chile. Person-to-person transmission is unusual among hantaviruses but has been documented for Andes virus, making household and healthcare contacts part of the public-health response.
After a prodrome of fever, headache and myalgia, capillary permeability rises abruptly. Fluid leaves the pulmonary circulation, oxygenation fails and hypotension can require ventilation and extracorporeal support. There is no approved therapeutic; intensive supportive care is the standard, and ribavirin has not shown a reliable benefit once cardiopulmonary disease is established.
BX-733 (Hantrelvir) is a selective S1PR1 agonist intended as a host-directed endothelial stabiliser. S1PR1 signalling helps maintain vascular-barrier integrity; the candidate is being developed in intravenous and oral forms to address the transition from monitored early disease to the rapidly progressive leak phase. It targets the host vascular response rather than the hantavirus polymerase.
Programme: BX-733 (Hantrelvir) — Phase 1, RIDGELINE-1
Conditions in scope
- Hantavirus cardiopulmonary syndrome
- Andes orthohantavirus infection
- Related New World hantavirus syndromes
- Post-exposure monitoring in recognised contacts
At a glance
- Andes case fatality approximately 35–40%
- Rodent-borne; Andes person-to-person spread documented
- Rapid pulmonary capillary leak and shock
- No approved therapeutic
Therapeutic area · Risk Group 3
Orthopoxvirus Disease
Clade I mpox causes more severe disease than the clade II outbreak lineage, particularly in children and people with advanced HIV. Reported case fatality has ranged from 1.4 to 3.3 per cent in clade I outbreaks.
Mpox is caused by an orthopoxvirus. Clade I transmission has historically involved zoonotic exposure and household contact in Central Africa, with sustained person-to-person spread also documented. Lesions, respiratory secretions and contaminated materials can transmit infection; severe disease may include extensive skin and mucosal involvement, bacterial superinfection, ocular complications, pneumonia or encephalitis. The World Health Organization declared a public health emergency of international concern for the clade I outbreak in August 2024.
Smallpox vaccines and antivirals exist in some jurisdictions, but access, licensing and evidence differ by indication and country. Tecovirimat is authorised for smallpox in the United States, not as a universally authorised treatment for mpox, and severe clade I disease still has no consistently available, indication-specific treatment. Supportive care and access to specialist protocols remain uneven where the burden is greatest.
BX-1140 (Poxavir) is a second-generation inhibitor of the p37 envelope protein encoded by F13L. By interfering with intracellular wrapping and extracellular virion formation, it is intended to reduce the spread of orthopoxvirus from infected cells. Oral and intravenous forms are being studied for clade I mpox and other orthopoxvirus disease; the candidate remains investigational.
Programme: BX-1140 (Poxavir) — Phase 1, MERIDIAN-1
Conditions in scope
- Clade I mpox
- Clade II mpox
- Orthopoxvirus disease in immunocompromised patients
- Complications of smallpox vaccination
At a glance
- Clade I reported case fatality 1.4–3.3%
- More severe disease in children and advanced HIV
- WHO emergency declared in August 2024
- No universally authorised mpox treatment
Therapeutic area · Risk Group 3
Phlebovirus & Arboviral Encephalitis
Rift Valley fever is usually a self-limiting febrile infection, but a minority of patients develop retinitis, encephalitis or haemorrhagic disease. The severe forms can carry case fatality above 50 per cent.
Rift Valley fever virus is maintained in livestock and mosquitoes, with heavy rain and flooding enabling explosive livestock epizootics. People are infected by mosquito bites or by contact with blood, organs and other tissues from infected animals. Human-to-human transmission has not been a demonstrated driver of outbreaks. The disease is endemic in much of sub-Saharan Africa and has caused outbreaks outside Africa, including on the Arabian Peninsula.
Most human infections cause fever, weakness and headache and resolve without lasting illness. Severe disease can damage the retina and cause permanent visual loss, inflame the brain, or produce haemorrhage and multi-organ failure. A licensed veterinary vaccine is available, but there is no licensed human vaccine and no licensed human therapeutic; treatment is supportive and early diagnosis is difficult because the initial illness resembles other febrile infections.
BX-1330 (Riftavir) combines a monoclonal antibody against the viral Gn glycoprotein with an inhibitor of the bunyavirus L-polymerase endonuclease. The fixed pair is intended to block entry while also interfering with viral RNA synthesis. It is being developed as an intravenous regimen for severe disease, when a patient may be unable to absorb oral medicine and the window before neurological or haemorrhagic complications is short.
Programme: BX-1330 (Riftavir) — Phase 1, HEADWATER-1
Conditions in scope
- Severe Rift Valley fever
- Rift Valley fever retinitis
- Rift Valley fever encephalitis
- Rift Valley fever haemorrhagic disease
At a glance
- Most infections are self-limiting
- Severe forms can exceed 50% case fatality
- Mosquito-borne and livestock-associated
- No licensed human vaccine or therapeutic
Therapeutic area · Risk Group 3 · Tier 1 select agent
High-Consequence Bacterial Infection
Melioidosis is a soil- and water-associated infection that can present as pneumonia, sepsis or localised disease, with relapse possible after a prolonged course of antibiotics.
Burkholderia pseudomallei is found in wet soil and surface water across northern Australia, South and Southeast Asia, and increasingly recognised areas of Africa and the Americas. Infection follows inoculation through broken skin, inhalation or ingestion; severe weather can bring the organism into closer contact with people. Most cases are not spread person to person. Diabetes, hazardous alcohol use, chronic lung or kidney disease and other host factors increase the risk of severe illness.
Melioidosis is estimated to cause approximately 165,000 cases and 89,000 deaths each year. Current care is not absent: intensive-phase intravenous ceftazidime or meropenem is followed by a long oral eradication course, commonly trimethoprim-sulfamethoxazole. The problem is the duration, intracellular persistence, missed doses, relapse and resistance. No approved combination is designed to preserve beta-lactam exposure by blocking the organism’s principal efflux systems during that course.
BX-1620 (Meliovex) pairs a ceftazidime-class beta-lactam with an efflux-pump inhibitor. The beta-lactam binds penicillin-binding protein 3; the inhibitor blocks the periplasmic adaptor interface of the principal resistance-nodulation-division pumps, including AmrAB-OprA and BpeEF-OprC. The inhibitor is not intended to kill the organism on its own. The combination is being studied in intravenous and oral forms for intensive and eradication therapy.
Programme: BX-1620 (Meliovex) — Phase 1, REDLAND-1
Conditions in scope
- Melioidosis pneumonia
- Melioidosis bacteraemia and sepsis
- Localised melioidosis
- Intensive-phase and eradication therapy
At a glance
- Approximately 165,000 cases and 89,000 deaths yearly
- Environmental organism; usually not person-to-person
- Intrinsic resistance and prolonged treatment
- United States Tier 1 select agent
Therapeutic area · publication status
Area not disclosed
The area is real and active. The indication, biology and programme are withheld in this revision.
This is a fifth clinical-stage programme retained within the research portfolio. Its designation, indication and modality are not disclosed in this revision. Work in the area remains subject to Baxtra’s biosafety, ethics and patient commitments.
Programme 9 — designation, indication and modality withheld in this revision · internal revision 41
Publication status
- Area: real and active
- Indication: withheld
- Biology: withheld in this revision
- Programme: not disclosed in this revision
At a glance
- Clinical stage: fifth programme
- Designation: not disclosed
- Modality: not disclosed
- Material: retained but not published
The other half of the company
Alongside the medicines, Baxtra Surgical builds the imaging, robotics and biomaterials used in the operating room.